Antibiotic Treatment for Pneumonia and Other Infections

Introduction to Antibiotic Selection

Daptomycin is contraindicated for the treatment of pneumonia due to its inactivation by pulmonary surfactant, resulting in poor clinical outcomes and increased mortality 1

The Infectious Diseases Working Party guidelines recommend Linezolid (600 mg IV twice daily) as a preferred treatment option, which is superior to vancomycin for ventilator-associated pneumonia due to MRSA 2, 1
Linezolid has better penetration into epithelial lining fluid compared to vancomycin 3
Vancomycin (15 mg/kg IV every 8-12 hours, target trough 15-20 mg/mL) may be used as an alternative therapy, but higher trough concentrations may be needed for efficacy 3

Patients with renal impairment may prefer Linezolid as vancomycin requires dose adjustment and monitoring 3
Concomitant use of vancomycin with other nephrotoxic agents, such as aminoglycosides, increases the risk of nephrotoxicity 3
Consider MRSA coverage in patients with recent hospitalization, chronic hemodialysis, chronic wounds, indwelling catheters, or residence in long-term care facilities 2
Prior IV antibiotic use within 90 days, septic shock, and high risk for mortality are risk factors for requiring double gram-negative coverage 4

If vancomycin MIC >1 mg/L and no clinical improvement after 3 days, consider switching to Linezolid 2
For necrotizing pneumonia, consider adding clindamycin to reduce toxin production 5
For MRSA bloodstream infections with vancomycin MIC >1 mg/L, consider using Linezolid 2

Organism	Recommended Antibiotic
Chlamydophila pneumoniae	doxycycline, macrolide, levofloxacin, or moxifloxacin [6]
Legionella spp.	levofloxacin, moxifloxacin, or macrolide (azithromycin preferred) ± rifampicin [6]
Pseudomonas aeruginosa	an antipseudomonal cephalosporin, acylureidopenicillin/β-lactamase inhibitor, or carbapenem PLUS ciprofloxacin OR aminoglycoside + macrolide [6]
MSSA	oxacillin, nafcillin, or cefazolin [4]
MRSA	vancomycin or linezolid [7, 4]
Penicillin-susceptible organisms	penicillin G, amoxicillin, or amoxicillin/clavulanate [7]
Penicillin-resistant organisms	ceftriaxone, fluoroquinolones, or vancomycin [7]

The most effective approach to selecting antibiotics based on a susceptibility report is to choose the narrowest-spectrum agent to which the organism is susceptible, considering patient-specific factors and the site of infection, as recommended by the Infectious Diseases Society of America and the European Respiratory Society 7, 4

The standard duration of treatment is 7-10 days for uncomplicated pneumonia, as recommended by the British Thoracic Society 8
Minimum treatment duration is 5 days for uncomplicated pneumonia, as recommended by the Infectious Diseases Society of America 5
Cavitary pneumonia typically requires longer courses (2-4 weeks), according to the Infectious Diseases Society of America 5
MRSA bacteremia requires a minimum of 2 weeks of treatment for uncomplicated cases and 4-6 weeks for complicated cases 9
Monitor vancomycin trough levels (target 15-20 mg/mL) and expect clinical improvement within 48-72 hours, as suggested by the British Thoracic Society 8, 4
Obtain blood cultures if bacteremia is suspected, and identify and address any source of infection, such as empyema requiring drainage 9

Nursing home residents are at increased risk of pneumonia due to factors such as poor dentition, neurologic illness, impaired consciousness, and swallowing disorders 10
Consider patient-specific factors, such as renal function, drug interactions, previous fluoroquinolone exposure, and local resistance patterns, when selecting an antibiotic regimen, as suggested by the Infectious Diseases Society of America 7
Amoxicillin monotherapy (500-1000 mg three times daily) may be considered for previously untreated elderly patients, according to the British Thoracic Society 8
Levofloxacin is recommended at a dose of 750 mg once daily by the Infectious Diseases Society of America 5